Reuters details Ozempic, Wegovy and Zepbound prices inside Trump drug-pricing deals

Reuters published a company-by-company guide on September 1, 2026 to the terms inside the drug-pricing deals the Trump administration has struck with more than 20 manufacturers, including the clearest public breakdown so far of how those agreements treat GLP-1 obesity and diabetes drugs ^[1].

For Novo Nordisk, the semaglutide medicines Ozempic and Wegovy are priced at $350 a month through TrumpRx, down from list prices of about $1,000 and $1,350 a month, respectively ^[1]. Novo Nordisk also agreed to supply the insulins NovoLog and Tresiba at $35 a month through the same channel ^[1]. The Novo agreement was reached in November 2025 ^[1].

Eli Lilly agreed to offer its obesity medicines Zepbound, a tirzepatide, and orforglipron, sold as Foundayo, to Medicare beneficiaries at no more than $50 a month, with additional discounts for self-pay patients through LillyDirect ^[1]. The Zepbound multidose pen is listed at $299 a month at its lowest dose, with higher doses priced up to $449 ^[1]. Foundayo starts at $149 a month at its lowest dose through LillyDirect ^[1]. Lilly also agreed to sell the migraine treatment Emgality at $299 per pen and the diabetes medicine Trulicity at $389 a month through TrumpRx ^[1].

The government's TrumpRx.gov site shows different numbers for some of the same drugs. It lists Ozempic at $199 a month against an original price of $1,028, a Wegovy pen at $199 a month and a Wegovy pill at $149 a month against an original price of $1,349, and Zepbound at $299 a month against an original price of $1,087 ^[2]. The site says it has saved Americans more than $700 million ^[2]. The listings shown do not state which doses or how many days of medicine those prices cover ^[2].

The deals also rest on most-favored-nation pricing, which ties U.S. prices to those paid in other developed countries, plus sales through TrumpRx.gov and U.S. investment pledges in exchange for tariff relief ^[1]. A second wave announced in late August 2026 added agreements with nine more companies, including some smaller biotechs, offering drugs to state Medicaid programs at most-favored-nation prices ^[1].

Why it matters for patients

GLP-1 list prices have been the number most people see when coverage is denied or when a deductible has not been met, and the published terms cut those figures sharply for cash buyers ^[1][2]. Which price a patient actually sees depends on the channel: TrumpRx, LillyDirect, or a regular pharmacy counter.

The two published sets of prices do not match. Reuters reports Ozempic and Wegovy at $350 a month through TrumpRx ^[1], while the TrumpRx.gov site shows $199 for Ozempic and the Wegovy pen and $149 for the Wegovy pill ^[2].

Medicare beneficiaries are named specifically in the Lilly terms, with a $50 monthly cap on Zepbound and Foundayo ^[1]. Oral orforglipron, sold as Foundayo, is a daily pill rather than an injection, which matters for people who want to avoid shots ^[1].

Several practical details have not been disclosed. The published terms do not say when the $50 Medicare price begins, whether people with commercial insurance can access these prices, whether the figures cover every dose strength, or how long the terms last. It also has not been reported whether prior authorization rules change under the agreements.

What happens next

Announcements have continued in waves, with the second group of nine companies disclosed in late August 2026 ^[1]. No start dates for the GLP-1 prices described by Reuters, or for the TrumpRx listings, have been reported ^[1][2].